A new era of thrombocardiology, that is the „vascular” dose of rivaroxaban in the antithrombotic treatment of atherosclerotic diseases. Why, when and in whom? Review article
Article Sidebar
Published:
Jun 30, 2024
Keywords:
rivaroxaban, acetylsalicylic acid, chronic coronary syndrome, peripheral artery disease, anticoagulant therapy
Main Article Content
Abstract
The need to improve the efficacy of anticoagulant therapy in secondary prevention is indicated by the fact that intensive antiplatelet therapy only partially reduces cardiovascular risk. The results of the COMPASS study provide evidence that additional blocking of coagulation cascade may significantly affect the further prevention of major cardiovascular events in a selected population of patients. The current guidelines of the European Society of Cardiology consistently emphasize the high position of the vascular dose of rivaroxaban in combination with acetylsalicylic acid, which is undoubtedly not only a legacy of the excellent results of the COMPASS study, but also an extremely important element of modern and comprehensive treatment aimed at the greatest possible risk reduction of cardiovascular events.
Article Details
How to Cite
Barylski, M. (2024). A new era of thrombocardiology, that is the „vascular” dose of rivaroxaban in the antithrombotic treatment of atherosclerotic diseases. Why, when and in whom?. Medycyna Faktow (J EBM), 17(2(63), 232-239. https://doi.org/10.24292/01.MF.0224.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Baigent C, Blackwell L, Collins R et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373(9678): 1849-60.
2. Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018; 2(2): 188-98.
3. Eikelboom JW, Connolly SJ, Bosch J et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319-30.
4. Anand SS, Caron F, Eikelboom JW et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018; 71(20): 2306-15.
5. Fulcher J, O’Connell R, Voysey M et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397-405.
6. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059): 2532-61.
7. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957-67.
8. Yusuf S, Sleight P, Pogue J et al.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145-53.
9. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010; 70: 2153-70.
10. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
11. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005; 352(16): 1685-95.
12. Spronk HM, de Jong AM, Crijns HJ et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014; 101(3): 344-51.
13. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010; 31(1): 17-28.
14. Mitchell JR. Prostaglandins in vascular disease: a seminal approach. Br Med J (Clin Res Ed). 1981; 282(6264): 590-4.
15. European Cardiovascular Disease Statistics 2017 edition.
16. Visseren FLJ, Mach F, Smulders YM et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
17. Marx N, Federici M, Schütt K et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043-140.
18. Vrints C, Andreotti F, Koskinas KC et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; ehae177.
19. Mazzolai L, Teixido-Tura G, Lanzi S et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024; ehae179.
2. Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018; 2(2): 188-98.
3. Eikelboom JW, Connolly SJ, Bosch J et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319-30.
4. Anand SS, Caron F, Eikelboom JW et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018; 71(20): 2306-15.
5. Fulcher J, O’Connell R, Voysey M et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397-405.
6. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059): 2532-61.
7. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022): 957-67.
8. Yusuf S, Sleight P, Pogue J et al.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145-53.
9. Rupprecht HJ, Blank R. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010; 70: 2153-70.
10. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999; 340: 115-26.
11. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005; 352(16): 1685-95.
12. Spronk HM, de Jong AM, Crijns HJ et al. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014; 101(3): 344-51.
13. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010; 31(1): 17-28.
14. Mitchell JR. Prostaglandins in vascular disease: a seminal approach. Br Med J (Clin Res Ed). 1981; 282(6264): 590-4.
15. European Cardiovascular Disease Statistics 2017 edition.
16. Visseren FLJ, Mach F, Smulders YM et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
17. Marx N, Federici M, Schütt K et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043-140.
18. Vrints C, Andreotti F, Koskinas KC et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; ehae177.
19. Mazzolai L, Teixido-Tura G, Lanzi S et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024; ehae179.